Curriculum vitae
Professor Dr. med. Christoph Thomssen
Universitätsklinik und Poliklinik für Gynäkologie
Universitätsklinikum Halle-Kröllwitz
Ernst-Grube-Strasse 40
D-06097 Halle (Saale)
Germany
Tel.: +49-345-557-1847
Fax: +49-345-557-1501
e-mail: christoph.thomssen@medizin.uni-halle.de
Curriculum Vitae Professor Dr. med. Christoph Thomssen
2
Curriculum Vitae
Professor Dr. med. Christoph Thomssen
Name
Christoph Thomssen, born January 5, 1957 in Waldshut/Hochrhein
University education
1976 - 1978
1978 - 1983
1982 - 1983
1983
1989
1998
2001
2004
Medical School at the Georg-August-Universität Göttingen (preclinical part)
Medical School at the Technische Universität München (clinical part)
Medical internship
Graduation in medicine (M.D., „Approbation“)
M.D. thesis (“Dr. med.”). Thesis advisor: Prof. Dr. med. H. J. Möller,
Department of Psychiatry, Technische Universität Munich)
Lecturer’s thesis (“Privatdozent”) at the Faculty of Medicine of the University
Hamburg
University-Professor for Obstetrics and Gynaecology at the University
Hamburg
University-Professor for Obstetrics and Gynaecology at the Martin-LutherUniversity Halle-Wittenberg (Ordinarius))
Professional appointments
1984 - 1986
1986 - 1996
1991
1992
1996
2003
2004
Residency at the Department of Obstetrics and Gynaecology of the District
Hospital Fürstenfeldbruck (Director: Dr. med. Sixtus Keck)
Residency and Fellowship at the Department of Obstetrics and Gynaecology of
the Technische Universität München (Director: Prof. Dr. med. Henner Graeff)
Specialist's degree in Obstetrics and Gynaecology (German National Board
Examination)
Senior physician at the Department of Obstetrics and Gynaecology of the
Technische Universität Munich
Senior physician and assistant director at the Department of Obstetrics and
Gynaecology, University of Hamburg (Director: Prof. Dr. med. Fritz Jänicke)
Director (comm.) of the Department of Gynecology at the University Halle / S
Director of the Department of Gynaecology at the University Halle / S
Subjects of Research
Clinical Oncology: Breast cancer: treatment of primary disease and recurrence; adjuvant
and palliative therapy, prognostic and predictive factors; endocrine therapy,
chemotherapy incl. dose-intense chemotherapy; axillary dissection, quality of
life. Ovarian Cancer: secondary surgery. Cervical Cancer: neoadjuvant
chemotherapy, surgery. Clinical Studies: Participation in study design and
coordination of 12 clinical studies; participation total in more than 35 studies.
Obstetrics:
Prenatal diagnosis, Doppler sonography.
Memberships:
American Association of Cancer Research (AACR), Deutsche Krebsgesellschaft (DKG),
Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), Arbeitsgruppe
Gynäkologische Onkologie (AGO), EORTC Biomarker and Receptor Study Group (RBSG),
EORTC Breast Cancer Cooperative Group (BCCG), Tumorzentrum Munich (Projektgruppen:
Curriculum Vitae Professor Dr. med. Christoph Thomssen
3
„Endometriumkarzinom/ Zervixkarzinom“, „Mammakarzinom“, „Ovarialkarzinom“),
Tumorzentrum Hamburg (AKOG), Nordostdeutsche Gesellschaft für Geburtshilfe und
Gynäkologische Onkologie (NOGGO), Medizinisch-Wissenschaftliche Gesellschaft für
Gynäkologie und Geburtshilfe in Sachsen-Anhalt e. V.
Publications
>80 original papers and review papers
32 book articles und published lectures
> 200 abstracts and letters
> 500 lectures and oral presentations
Clinical studies (listed only if participation in study design or coordination)
(*multicenter studies)
1. *Mitoxantrone single agent treatment in metastatic breast cancer
2. *Triple-M as neoadjuvant therapy of locally advanced breast cancer
3. Oxytocin IV vs. oxytocin as intranasal spray in contraction stress test
4. *Adjuvant chemotherapy in node-negative breast cancer guided risk adapted selection by
tumorbiologic prognostic factors: uPA und PAI-1 (multicentric trial supported by DFG).
5. *High dose-intensity chemotherapy in high-rik breast cancer (N1biii or >10 ax. Lnn.): diEC vs. EC/CMF.
6. Taxol in first line-treatment of metastatic breast cancer.
7. Fibronectin in cervical mucus as predictor of response to labour inducing measures
(randomised trial).
8. *Epirubicin and paclitaxel in first line-chemotherapy in metastatic breast cancer: Phase IIstudy.
9. *Epirubicin and paclitaxel in comparison to epirubicin and cyclophosphamide in first-line
therapy of patients with metastatic breast cancer.
10. *Adjuvant chemotherapy (ETC) in a dose-intense approach with shortened intervals
versus sequential standard chemotherapy (ECT) in high-risk patients with nodepositive breast cancer (4 - 9 ax. Lnn.). A Phase-II study.
11. *Sequential chemotherapy (ETC)  Epoetin- in a dose-intense approach with shortened
intervals versus sequential standard chemotherapy (ECT) in high-risk patients with
node-positive breast cancer (4 - 9 ax. Lnn.). Open randomised, prospective, multicentric
phase III-therapy optimization.
12. *Randomised comparison of a neoadjuvant, dose-intense sequential chemotherapy with
epirubicin and paclitaxel versus a neoadjuvant chemotherapy with epirubicin and
paclitaxel in standard dose in patients with primary breast cancer.
13. *Adjuvant chemotherapy in node-negative breast cancer patients guided by prognostic
(uPA/PAI-1) and predictive (c-erbB-2) factors. A multicentric, prospective and
randomized trial on the predictive value of c-erbB-2 overexpression in adjuvant
chemotherapy of high-risk node-negative breast cancer patients defined by
Curriculum Vitae Professor Dr. med. Christoph Thomssen
4
tumorbiological factors (uPA/PAI-1). (Europäische Multicenterstudie, Studienleitung).
(LKP)
14. *Cardiac safety of recombinant humanized anti-p185HER-2/neu monoclonal antibody
trastuzumab in combination with epirubicin/cyclophosphamide as first line therapy in
anthracycline-naïve patients with HER-2/neu overexpressing metastatic breast cancer
15. *Phase II-trial Taxol/5-FU in patients with metastatic breast cancer recurrent after highdose chemotherapy with stem cell support.
16. *Phase I/II-trial on concurrent radio-chemotherapy in inoperable cervical cancer.
17. *HERA – Herceptin adjuvant in HER-2 overexpressin breast cancer (Member of the
international steering committee).
18. *GAIN - Phase III- trial to compare ETC vs. EC-TX and Ibandronat vs. observation in
patients with node-positiv primary breast cancer
19. *ATHENA - Open-label study of bevacizumab (AVASTIN®) plus taxane monotherapy or
in combination for the first-line treatment of patients with locally recurrent or metastatic
breast cancer (LKP)
20. *ALTTO – Adjuvant Lapatinib and/or Trastuzumab treatment optimisation study